Greenville Memorial Hospital’s Comprehensive Stroke Center and Greer Memorial Hospital’s Primary Stroke Center are dedicated to helping our community achieve the best possible outcomes following stroke, and implementing the American Heart Association/American Stroke Associations® Get With The Guidelines® program has helped us accomplish that by making it easier for our
teams to put proven knowledge and guidelines to work on a daily basis.
Gold Plus Recognition
“Hospitals receiving Get With The Guidelines® Gold Plus Achievement Award have reached an aggressive goal of treating patients with 85 percent or higher compliance to core standard levels of care as outlined by the American Heart Association/American Stroke Association® for 2 consecutive calendar years. In addition, those hospitals have demonstrated 75 percent compliance to (four out of ten heart failure quality measures or seven out of ten stroke quality measures) during the 12-month period.”
Target: Stroke Honor Roll Elite Plus
“Hospitals achieving Time to Intravenous Thrombolytic Therapy ≤ 60 minutes in 75 percent or more of applicable acute ischemic stroke patients treated with IV tPA AND door-to-needle time. Time to Intravenous Thrombolytic Therapy within 45 minutes in 50 percent of applicable acute ischemic stroke patients treated with IV tPA to improve quality of patient care and outcomes.”
Intravenous thrombolytic (IV tPA) is a clotbuster drug designed to break up the clot in blood vessel that is blocking the blood flow to brain tissue. Currently, the drug is administered to patients who arrive to the hospital within 4.5 hours of onset of stroke symptoms.
Mechanical thrombectomy (MT) is a treatment performed by inserting a catheter into the artery that is blocked and removing the obstruction directly. Currently, this treatment is recommended up to 24 hours after the onset of symptoms for selected patients.
|Greenville Memorial Emergency Department||Comprehensive Stroke Center Peer Group|
Hospital Arrival to IV tPA Start
|Median: 23 minutes (n=79)||Median: 38 minutes|
|Percent of patients admitted with ischemic stroke receiving IV tPA||23.1% (n=83)||11.1%|
|Hospital Arrival to MT start||Median: 68.5 minutes (n=84)||Median: 67 minutes|
|Percent of patients admitted with ischemic stroke receiving MT||27% (n=97)||13.2%|
|Percent of patients admitted with ischemic stroke receiving either reperfusion therapy||47.6% (n=171)||29.3%|
Results from the GWTG-Stroke Registry for October 2019 to March 2019
Stroke is the fifth leading cause of death and a leading cause of disability in adults. It is a complex disease which requires many specialized resources to treat.
|Greenville Memorial Hospital||Comprehensive Stroke Center Peer Group|
Results from the GWTG-Stroke Registry for October 2018 to March 2019
Our Center is active in clinical trials research to advance the science of stroke care and neuroendovascular surgical procedures through participation in clinical trials and collaboration with various industry sponsors, universities, and the National Institute of Health (NIH). As a member of the NIH’s StrokeNet network, we participate in a number of clinical trials in stroke prevention, treatment, and recovery. In particular, our involvement in the SE-CoAST region of NIH StrokeNet, which includes MUSC Stroke Center, USC Neurology, Augusta University Medical Center, and Guilford Neurological Associates, affords us opportunities to engage in phase III clinical trials involving drugs and devices, as well as data analyses trials.
The Cerebrovascular and Stroke Center is participating in the following clinical trials:
|Clinical Trial||ClinicalTrials.gov Identifier||Study Name|
|ARCADIA||NCT03192215||AtRial Cardiopathy and Antithrombotic Drugs In Prevention After Cryptogenic Stroke (ARCADIA)|
|MOST||NCT03735979||Multi-arm Optimization of Stroke Thrombolysis (MOST)|
|Sleep SMART||NCT03812653||Sleep for Stroke Management and Recovery Trial (Sleep SMART)|
|PACESETTER||NCT03401489||Program to Avoid Cerebrovascular Events Through Systematic Electronic Tracking and Tailoring of an Eminent Risk-factor (PACESETTER)|
|MaRISS||NCT02072681||Mild and Rapidly Improving Stroke Study (MaRISS)|
|ARAMIS||NCT02478177||Addressing Real-world Anticoagulant Management Issues in Stroke (ARAMIS)|
|TARGET||NCT01748903||Intracranial Aneurysm Coiling Registry (TARGET)|
|RE-SPECT ESUS||NCT02239120||Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS)|
|RAGE||NCT03252314||Ruptured Aneurysms Treated With Hydrogel Coils (RAGE)|
|VIGOR||NCT03767842||Volumetric Impedance to Guide Stroke Response (VIGOR)|
|RIVER||NCT03556085||Clinical Evaluation of the Serenity River Stent System to Treat Idiopathic Intracranial Hypertension|
|INVEST-Registry||NCT02661672||Minimally Invasive Endoscopic Surgical Treatment With Apollo/Artemis in Patients With Brain Hemorrhage: A Prospective Multicenter Registry|
|INVEST-Feasibility||NCT02654015||A Single Arm, Feasibility Study of Minimally Invasive Endoscopic Surgical Treatment With Apollo for Supratentorial Intracerebral Hemorrhage (ICH)|
|Greenville Memorial Hospital||Peer Group|
Stroke within 30 days
July 2017 – June 2019
|Carotid Artery Stenting|
Incidence of Death, Stroke or MI
Cumulative through Dec. 2019
Have questions about Stroke?
Visit the American Heart Association website for reliable stroke information.
Have questions about Clinical Research Trials?
Visit Clinical Research Trials and You for frequently asked questions.
For additional information, please contact:
Tory Holt, Clinical Research Coordinator, Stroke Program, at email@example.com or 864-455-3438.
Daniel Burch, Clinical Research Coordinator, Stroke Program, at firstname.lastname@example.org or 864-455-1027.
Lisa Carson, Clinical Research Coordinator, Neuroendovascular Surgery, at email@example.com or 864-469-1595.